DISCLAIMER

- This session was conducted for members of county-based teams in CA that are working to expand access to Medications for Addiction Treatment in jails and drug courts. The project is funded through California's Department of Health Care Services with State Opioid Response funding from SAMHSA. The content is being made available to all interested parties.
- Please note this content has not been professionally edited and the session was conducted using Zoom.





HEALTH Management Associates



Opioid Withdrawal

December 3, 2020

Copyright © 2020 Health Management Associates, Inc. All rights reserved. The content of this presentation is PROPRIETARY and CONFIDENTIAL to Health Management Associates, Inc. and only for the information of the intended recipient. Do not use, publish or redistribute without written permission from Health Management Associates, Inc.

TODAY'S PRESENTERS

wellpath

Stephanie Ruckman, DNP, FNP-BC, MBA, CCHP National Director of Jail MAT Programs, Wellpath StRuckman@Wellpath.us

HMA

SHANNON ROBINSON, MD, FASAM Principal, Health Management Associates

srobinson@healthmanagement.com

Donna Strugar-Fritsch, BSN, MPA, CCHP *Principal, Health Management Associates*

dstrugarfritsch@healthmanagement.com

Disclosures:

Dr. Robinson and Donna Strugar-Fritsch disclose that they are employees of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of healthcare clients.

HEALTH MANAGEMENT ASSOCIATES





Nelly Blanco, BSN, RN, PHN Senior Comprehensive Registered Nurse, Orange County Correctional Health Services <u>nblanco@ochca.com</u>

Kathy Minnicucci, BSN, RN, PHN Senior Nurse, Orange County Correctional Health Services <u>kminnicucci@ochca.com</u>

Jessica Sepulveda, RN Staff Nurse, Orange County Correctional Health Care Services jsepulveda@ochca.com

LEARNING OBJECTIVES

At the end of presentation participants will be able to: Identify signs and symptoms of opioid withdrawal

 Understand the rational for the treatment recommendations for opioid withdrawal



Mr. Johnson presents to your jail and reports having last used heroin 4 hours ago. During his nursing assessment you tell Mr. Johnson...

- 1. he will not get treatment for withdrawal symptoms
- 2. he will get medication for nausea and vomiting
- 3. he will get evidence-based treatment upon withdrawal
- 4. you don't care if he has withdrawal or not




WHY USE MEDICATION FOR OPIOID WITHDRAWAL?

• Treatment is more effective than abrupt cessation due to risk of relapse, OD & death

"Forced withdrawal can undermine a person's willingness to engage in treatment in the future, compromising the likelihood of long-term recovery"

- NCCHC Promising Practice Guidelines
- Avoid deaths
- Avoid litigation
- Patients more agreeable; "they bloom like flowers"
- Facility cleaner and safer
- Improve reward system and motivation





PEOPLE DIE FROM WITHDRAWAL BECAUSE

- Failure to take withdrawal seriously
- Failure to recognize withdrawal, because of other conditions
- Failure to use opioid agonists to treat withdrawal
- Failure to adequately and closely monitor withdrawal
- Masking of underlying lifethreatening conditions by withdrawal

- Muscle aches
- Rhinorrhea
- Insomnia

Fever

Nausea & Vomiting

Opioid Withdrawal

- Diarrhea
- Tachycardia
- Tachypnea
- Anxiety
- LacrimationDysphoria

COVID-19

- Fever
- Cough
- Shortness of breath
- Muscle aches
- Rhinorrhea
- Insomnia
- Nausea & Vomiting
- Diarrhea
- Tachycardia
- Tachypnea
- Anxiety

HISTORICAL TREATMENT OF OPIOID WITHDRAWAL: "COMFORT MEDICATIONS"

- 1. Clonidine: start 0.1 mg bid for bone pain & arousal; may increase dose, but watch for hypotension
- 2. Imodium (loperamide) 4mg 1-2 tabs q1 hr for diarrhea, NTE 16 mg/day
- 3. Motrin (ibuprofen) 600 mg q 6hr for bone pain or NSAID of your choice
- 4. Tylenol (acetaminophen) 975 mg up to qid for pain not relieved by NSAIDs
 - Can use both Tylenol and NSAIDS at the same time
- 5. Benadryl (diphenhydramine) 25 to 50 mg q6hr for nasal congestion, insomnia or anxiety
- 6. Compazine (prochlorperazine) 10mg qid for nausea/vomiting; give by any route available
- 7. Bentyl (dicyclomine) 10 mg qid for abdominal cramping, not relieved by controlling diarrhea
- 8. Valium (diazepam):10-15 mg for muscle spasms and insomnia

HEALTH MANAGEMENT ASSOCIATES

This approach is not recommended; not as effective or easy

ASAM GUIDELINES 2020: OPIOID WITHDRAWAL

Using opioid agonists is recommended over abrupt

Initiate buprenorphine after objective evidence of withdrawal

Provide adequate buprenorphine to suppress withdrawal symptoms

Alpha 2 adrenergic agonists are less effective than methadone and buprenorphine

Sources: Focus Update, ASAM National Practice Guideline Treatment of Opioid Use Disorder 2020 Gowing, L et. Al. (2017) Buprenorphine for managing opioid withdrawal Cochrane Database Sys Review 2(2)



WHO IS AT RISK OF WITHDRAWAL




Exposure to steady state level of a substance causes neuroadaptation; this leads to the spontaneous onset of withdrawal symptoms when the substance is abruptly stopped or greatly decreased.

Opioid	Onset	Peak	Duration
Heroin	6 hours	By 3 days	4-7 days
Methadone	1-2 days	By 7 days	12-14 days
Fentanyl short acting	6 hours		
Fentanyl long acting	24-36 hours		

- Higher intensity withdrawal comes from:
 - Higher steady state drug levels
 - Longer duration of exposure
 - Rapid drug clearance from the body leads to more rapid onset of withdrawal and more intense withdrawal
- Duration of withdrawal is dependent upon the duration of the drug being consumed



WITHDRAWAL



	Onset	Peak	Duration
Naloxone	e minutes		20 minutes
Naltrexone	minutes		1-2 days
Buprenorphine	minutes		1-2 days

Treatment for Precipitated Withdrawal

Continue Buprenorphine

- Give another dose
- May relieve symptoms

Stop Buprenorphine

- Treat withdrawal symptoms
- Start again tomorrow

GOALS/ BENEFITS OF WITHDRAWAL MANAGEMENT

Goals	Benefits
Suppress withdrawal symptoms	Improved retention in treatment
Reduce or discontinue illicit opioid use	Decreases relapse
Decrease cravings	Improved abstinence
Blunt effects of illicit opioids if used	Decreased overdoses
Minimize side effects	
Maximize facility cleanliness (vomiting and diarrhea increase transmission of COVID)	
Maximize safety of facility	

Source: O'Connor PG. JAMA. 2005; Mattick RP, Hall WD. Lancet. 1996



OPIOID WITHDRAWAL SYMPTOMS & SIGNS

- Symptoms are reported
- Signs are observed
- Symptoms and sign are generally on a continuum
- Most symptoms can be feigned except piloerection- DO NOT STOP WITH SYMPTOMS
- Signs aren't feigned, they are observed- USE YOUR CLINICAL JUDGEMENT
- COWS has become the standard assessment of withdrawal
- Other tools could be used
 - Clinical Institute Narcotic Assessment

Clinical Opiate Withdrawal Scale (COWS):

Scores:

- 5-12 mild
- 13-24 moderate
- 25-36 moderate to severe
- >36 severe

HEALTH MANAGEMENT ASSOCIATES

More important than the score is objective evidence of withdrawal



Patient's Name: Date and Time / / Reason for this assessment: Resting Pulse Rate: beats/minute GI Upset: over last 1/2 hour Measured after patient is sitting or lying for one minute 0 no GI symptoms 0 pulse rate 80 or below 1 stomach cramps 1 pulse rate 81-100 2 nausea or loose stool 2 pulse rate 101-120 3 vomiting or diarrhea 4 pulse rate greater than 120 5 multiple episodes of diarrhea or vomiting Tremor observation of outstretched hands Sweating: over past 1/2 hour not accounted for by room temperature or patient activity. 0 no tremor 0 no report of chills or flushing 1 tremor can be felt, but not observed 1 subjective report of chills or flushing 2 slight tremor observable 2 flushed or observable moistness on face 4 gross tremor or muscle twitching 3 beads of sweat on brow or face 4 sweat streaming off face **Restlessness** Observation during assessment Yawning Observation during assessment 0 able to sit still 0 no yawning 1 reports difficulty sitting still, but is able to do so 1 yawning once or twice during assessment 3 frequent shifting or extraneous movements of legs/arms 2 yawning three or more times during assessment 5 unable to sit still for more than a few seconds 4 yawning several times/minute Pupil size Anxiety or Irritability 0 pupils pinned or normal size for room light 0 none 1 pupils possibly larger than normal for room light 1 patient reports increasing irritability or anxiousness 2 pupils moderately dilated 2 patient obviously irritable or anxious 5 pupils so dilated that only the rim of the iris is visible 4 patient so irritable or anxious that participation in the assessment is difficult Bone or Joint aches If patient was having pain Gooseflesh skin previously, only the additional component attributed 0 skin is smooth to opiates withdrawal is scored 3 piloerrection of skin can be felt or hairs standing up 0 not present on arms 1 mild diffuse discomfort 5 prominent piloerrection 2 patient reports severe diffuse aching of joints/muscles 4 patient is rubbing joints or muscles and is unable to sit

still because of discomfort Runny nose or tearing Not accounted for by cold symptoms or allergies Total Score The total score is the sum of all 11 items 1 nasal stuffiness or unusually moist eyes 2 nose running or tearing Initials of person 4 nose constantly running or tears streaming down cheeks

completing assessment:



0 not present

Source: Wesson and Ling. 2003 The clinical opioid withdrawal

I COWS- DECIDE & TRAIN: ONLY USE ANCHORS OR USE ALL NUMBERS

- Pulse (objective)
 - 0 pulse<80
 - 1 pulse 81-100
 - 2 pulse 101-120
 - 4 pulse >120
- Sweating (over past 30 min-subjective & objective)
 - 0 no report of chills/flushing
 - 1 report of chills/ flushing
 - 2 flushed or observable moistness
 - 3 beads of sweat on face
 - 4 sweat streaming off face
- Restlessness (subjective & objective)
 - 0 able to sit still
 - 1 reports difficulty but able to sit still
 - 3 frequent shifting or moving extremities
 - 5 unable to sit still for more than a few seconds

HEALTH MANAGEMENT ASSOCIATES

- Pupil size (objective)
 - 0 pinned or normal
 - 1 possibly larger
 - 2 moderately dilated
 - 5 so dilated only rim showing
- Bone/ joint aches (subjective & objective)
 - 0 not present
 - 1 mild diffuse discomfort
 - 2 reports severe diffuse discomfort
 - 4 rubbing & unable to sit still

Patients should not exceed the lowest score in most categories without some objective evidence of withdrawal. NIDA

I COWS

- Runny nose/ tearing (subjective & objective)
 - 0 none
 - 1 stuffy/ moist
 - 2 runny or tearing
 - 4 constantly running/ tearing
- GI upset (subjective & objective)
 - 0 no GI symptoms
 - 1 stomach cramps
 - 2 nausea or loose stool
 - 3 vomiting or diarrhea
 - 5 multiple episodes
- Tremor (subjective & objective)
 - 0 none
 - 1 tremor can be felt but not seen
 - 2 slight tremor observable
 - 4 gross tremor or twitching

- Yawning (objective)
 - 0 none
 - 1 Once or twice during assessment
 - 2 Three during assessment
 - 4 Several times/ minute
- Anxiety/ Irritability (subjective & objective)
 - 0 none
 - 1 reports anxious or irritable
 - 2 obviously anxious or irritable
 - 4 so anxious or irritable participation is difficult
- Gooseflesh (objective)
 - 0 skin is smooth
 - 3 piloerection felt or visible
 - 5 prominent piloerection



IMPORTANCE OF ASSESSMENT

- Taking care of the patient
 - A good history enables prediction of onset of moderate withdrawal
 - Last use
 - Amount used/day
- Drastic change
- Clinical judgement

- Protocol
- Magic # to initiation buprenorphine





TREATMENT OF OPIOID WITHDRAWAL: AGONISTS

Buprenorphine

- Objective evidence of withdrawal
- Initial dose 2-8mg
- Can monitor for 30 minutes, but not required
- Repeat or increase dose same or next day
- Patient stabilizes 1-2 days
- Target dose 16mg/ day



Methadone

- Evidence of withdrawal
- Initial dose 10-30mg
- May give second dose after 3 h
- Dose increase above 30 mg cannot occur for 7 days
- Patient stabilizes in weeks
- Target dose 60-120mg/ day

Giving other medication is not necessary if you treat all withdrawal symptoms with buprenorphine

TAPER BUPRENORPHINE FOR OPIOID WITHDRAWAL OR MAINTAIN BUPRENORPHINE FOR OPIOID WITHDRAWAL AND OPIOID USE DISORDER

- Taper over 4-30 days
- Data doesn't support this
- 85% of patient relapse within a year
- Relapse may lead to death
- 71% of deaths within 2 weeks of release from incarceration are due to overdose
- Medication decreases overdose death by 60%

Reasons for relapse:

- Ongoing withdrawal symptoms
- Protracted withdrawal
 - Fatigue, insomnia
 - Poor tolerance to stress & pain
 - Cravings
- Triggers (conditioned cues)

Source: Kleber (2007) Dialogues Clin Neuroscience





ASAM

- Using opioid agonists is recommended over abrupt cessation
- Initiate buprenorphine after objective evidence of withdrawal
- Provide adequate buprenorphine to suppress withdrawal symptoms

NCCHC



- Using opioid agonists is recommended over abrupt cessation
- Screen everyone for withdrawal
- Initiate buprenorphine after evidence of moderate withdrawal

✓ Take a good history ✓ Use the COWS but most importantly **Use your** observations & judgement



QUESTIONS





EVALUATION

- 1. Overall, today's webinar was:
 - A. Very useful
 - B. Somewhat useful
 - C. Not very useful
 - D. Not useful at all
- 2. The material presented today was:
 - A. At the right level
 - B. Too basic
 - C. Too detailed



CONTACT US

FOR ANY QUESTIONS OR COMMENTS

MATinCountyCJ@healthmanagment.com

SHANNON ROBINSON srobinson@healthmanagement.com

Contact your HMA coach to discuss how to apply today's learnings.

A link to the recording of today's webinar and the slides will be posted on Addictionfreeca.org Feel free to forward to others on your team.

HEALTH MANAGEMENT ASSOCIATES



UPCOMING EVENTS



Learning Collaborative #2 12/16/2020



Co-Occurring Disorders Webinar 1/21/2021



Pretrial Services Webinar 2/23/2021



Alcohol Withdrawal Management Webinar February 2021 (Date TBD)



REFERENCES/ RESOURCES

- Fiscella, K et al. (2020) J Correctional Health Care 26 (2) 183-193.
- Rich, JD, et al. Continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. The Lancet Volume 386, ISSUE 9991, P350-359. Methadone trial
- Mattick, RP, et al. (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Systematic Review.
- Mattick, RP, et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Systematic Review.
- Green, TC, et al. (2018) Postincarceration fatal overdose after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry 75(4) 405-407.
- Sordo, L. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (2017); 357: j1550.
- Walley, A. et al. Association between mortality rates and medication and residential treatment after inpatient medically managed opioid withdrawal: a cohort analysis, Addiction (2020)
- Moore, KE, et al. (2018). Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared with forced withdrawal. Journal of Addiction Medicine, 12(2), 156–162.
- Sheriff's Association & National Commission on Correctional Health Care. (2018) Jail-Based Medication Assisted Treatment: Promising Practice Guidelines and Resources For the Field.
- Recent Legal Review of MAT: *https://opioidresponsenetwork.org/documents/MOUDConference2020/Gabrielle%20de%20la%20Gueronniere-%20MOUD%20presentation%20RI.pdfThe 2020 Focus Update, ASAM National Practice Guideline Treatment of Opioid Use Disorder; <u>https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2</u>
- Wesson and Ling. 2003 The clinical opioid withdrawal scale. Journal of Psychoactive Drugs 35 (2): 253-9. <u>https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications</u>
- Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009 Nov 1;105(1-2):154-9.
- Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet. 2003 Feb 22;361(9358):662-8.
- O'Connor PG. Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence. JAMA. 2005;294(8):961–963.
- National Institute of Drug Abuse, https://www.drugabuse.gov/sites/default/files/ClinicalOpiateWithdrawalScale.pdf
- Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-70.

